Asset profile
GW117
Small molecule
Evidence outlook · lead readout
NCT06796868 · Major Depressive Disorder (MDD)
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT06796868: The study was randomized, quadruple-blinded, placebo-controlled, and included 280 participants, with the primary outcome being the clinical HAMD-17 depression score. Because the registry does not report whether the primary comparison was statistically significant, the evidence is currently limited despite the strong trial design.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.